Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Rhode Island: - Providence Veterans Administration Hospital — Providence, Rhode Island
- Smilow Cancer Hospital Care Center - Westerly — Westerly, Rhode Island
Phase 3 Recruiting Industry
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …
Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Rhode Island: - Lifespan Cancer Institute — Providence, Rhode Island
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Rhode Island: - Smilow Cancer Hospital Care Center - Westerly — Westerly, Rhode Island
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Rhode Island: - Women and Infants Hospital of Rhode Island — Providence, Rhode Island
Phase 1, Phase 2 Recruiting Industry
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors
Sponsor: AstraZeneca
NCT ID: NCT05797168
Sites in Rhode Island: - Research Site — Providence, Rhode Island
- Research Site — Providence, Rhode Island
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
Sponsor: AstraZeneca
NCT ID: NCT06996782
Sites in Rhode Island: - Research Site — Providence, Rhode Island
- Research Site — Providence, Rhode Island
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human (FIH), open-label, multi-site study which will evaluate the safety, efficacy, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.
Sponsor: BioNTech SE
NCT ID: NCT06750185
Sites in Rhode Island: - Rhode Island Hospital — East Providence, Rhode Island
Phase 1, Phase 2 Recruiting Industry
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the P…
Sponsor: 7 Hills Pharma, LLC
NCT ID: NCT06362369
Sites in Rhode Island: - Brown University Health Cancer Institute — Providence, Rhode Island
Recruiting Academic/Other
This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treatment toxicity.
Sponsor: Jun Zhang, MD, PhD
NCT ID: NCT04680377
Sites in Rhode Island: - Rhode Island Hospital, Brown University — Providence, Rhode Island